Based on several evidence the American Diabetes Association and the European Association for the Study of Diabetes guidelines (GLs) strongly recommend the use of GLP-1 RA and SGLT2-i in patients with T2D at high CV risk or with established atherosclerotic CVD [27, 28] as well as the prescriptions of antihypertensive, antithrombotic, and lipid-lowering treatments for CV protection [3, 27, 28]. This evidence concerns the gene GLP1R and diabetes mellitus.